Get the Stockscreener App
4.51
1.96%
-0.09
After Hours:
4.51
Vanda Pharmaceuticals Inc stock is traded at $4.51, with a volume of 367.82K.
It is down -1.96% in the last 24 hours and up +4.64% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$4.60
Open:
$4.58
24h Volume:
367.82K
Relative Volume:
0.81
Market Cap:
$266.49M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
86.07
EPS:
0.0524
Net Cash Flow:
$12.42M
1W Performance:
-2.17%
1M Performance:
+4.64%
6M Performance:
-8.89%
1Y Performance:
-9.62%
1-Day Range:
$4.47
$4.58
1-Week Range:
$4.465
$4.65
52-Week Range:
$3.8092
$5.545
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.51 | 264.72M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Can Vanda Pharmaceuticals Inc. ride the EV waveJuly 2025 Rallies & Weekly Sector Rotation Insights - Lancaster City Council
Vanda Pharmaceuticals at H.C. Wainwright: Strategic Growth and Challenges - Investing.com
Vernal keratoconjunctivitis Pipeline Analysis & Clinical Trials, 2025, DelveInsight | iCo Therapeutics, Vanda Pharmaceuticals, Sylentis, Allakos - The Globe and Mail
Vanda Pharmaceuticals Inc. Attempts Reversal From Key SupportWeekly Trade Report & High Return Stock Watch Alerts - beatles.ru
Is Vanda Pharmaceuticals Inc. exposed to currency risksWeekly Profit Analysis & Free Technical Pattern Based Buy Signals - classian.co.kr
Will Vanda Pharmaceuticals Inc. Hold Gains Into CloseJuly 2025 PreEarnings & Real-Time Market Sentiment Alerts - beatles.ru
RSI Reset May Fuel Rebound in Vanda Pharmaceuticals Inc.2025 Market Trends & Stepwise Entry/Exit Trade Alerts - beatles.ru
Vanda Pharmaceuticals gets FDA orphan drug status for VGT-1849B - MSN
Vanda Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Decliners & Real-Time Market Sentiment Alerts - Newser
Multi asset correlation models including Vanda Pharmaceuticals Inc.July 2025 Short Interest & AI Enhanced Trade Execution Alerts - Newser
Will Vanda Pharmaceuticals Inc. benefit from rate cuts2025 Growth vs Value & Fast Entry and Exit Trade Plans - خودرو بانک
Technical analysis overview for Vanda Pharmaceuticals Inc. stockWeekly Trade Report & Weekly Breakout Stock Alerts - Newser
Trend analysis for Vanda Pharmaceuticals Inc. this weekBond Market & Weekly Momentum Stock Picks - Newser
Vanda Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 EndofMonth & Real-Time Volume Triggers - Newser
Can Vanda Pharmaceuticals Inc. lead its sector in growthJuly 2025 Rallies & Verified Entry Point Signals - خودرو بانک
How to read the order book for Vanda Pharmaceuticals Inc.Risk Management & Free Community Consensus Stock Picks - Newser
What the charts say about Vanda Pharmaceuticals Inc. todayJuly 2025 Update & High Accuracy Swing Entry Alerts - Newser
Wellington Management Group LLP Sells 82,958 Shares of Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Pharmaceuticals at Wells Fargo Conference: Strategic Growth and Innovation - Investing.com Australia
Why Vanda Pharmaceuticals Inc. is moving today2025 Price Targets & Free Real-Time Volume Trigger Notifications - Newser
Breakout Zone: What is Vanda Pharmaceuticals Inc.’s book value per shareTrade Exit Summary & Long-Term Capital Growth Ideas - خودرو بانک
How to build a dashboard for Vanda Pharmaceuticals Inc. stockEarnings Summary Report & Daily Momentum Trading Reports - Newser
Technical signs of recovery in Vanda Pharmaceuticals Inc.2025 Trading Recap & Fast Gaining Stock Strategy Reports - Newser
How institutional ownership impacts Vanda Pharmaceuticals Inc. stock2025 Sector Review & Safe Capital Preservation Plans - Newser
Charles Schwab Investment Management Inc. Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Is Vanda Pharmaceuticals Inc. stock poised for growthWeekly Volume Report & Low Risk Entry Point Tips - Newser
Regression analysis insights on Vanda Pharmaceuticals Inc. performancePortfolio Value Report & Expert Approved Momentum Ideas - Newser
Is Vanda Pharmaceuticals Inc. stock showing strong momentum2025 Technical Patterns & Detailed Earnings Play Strategies - خودرو بانک
Published on: 2025-09-03 23:56:45 - Newser
Vanda at Cantor Global: Strategic Growth Amid Challenges - Investing.com
Will Vanda Pharmaceuticals Inc. price bounce be sustainablePortfolio Performance Report & Verified Chart Pattern Signals - Newser
Heatmap analysis for Vanda Pharmaceuticals Inc. and competitorsJuly 2025 Market Mood & Fast Exit Strategy with Risk Control - Newser
Should you wait for a breakout in Vanda Pharmaceuticals Inc.2025 Key Highlights & High Conviction Investment Ideas - Newser
What does recent volatility data suggest for Vanda Pharmaceuticals Inc.Portfolio Risk Summary & Verified Entry Point Signals - Newser
Key metrics from Vanda Pharmaceuticals Inc.’s quarterly dataWeekly Stock Report & Momentum Based Trading Ideas - Newser
Is Vanda Pharmaceuticals Inc. reversing from oversold territoryForecast Cut & Expert Curated Trade Ideas - Newser
Is a relief rally coming for Vanda Pharmaceuticals Inc. holdersPortfolio Growth Summary & Weekly Top Gainers Alerts - Newser
Using Bollinger Bands to evaluate Vanda Pharmaceuticals Inc.Trade Performance Summary & Fast Exit and Entry Strategy Plans - Newser
Can Vanda Pharmaceuticals Inc. benefit from deglobalizationWeekly Stock Analysis & Expert Verified Stock Movement Alerts - خودرو بانک
Portfolio Update: Is Vanda Pharmaceuticals Inc. a play on infrastructure spending2025 Price Momentum & Daily Stock Trend Watchlist - خودرو بانک
Tools to assess Vanda Pharmaceuticals Inc.’s risk profile2025 Market Outlook & Verified Swing Trading Watchlist - Newser
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):